anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The current study aimed to evaluate the efficacy of delta frequency binaural beats stimulation in treatment of individuals with tinnitus having normal hearing sensitivity.
METHOD: Twenty-four individuals who reported bothersome tinnitus in the presence of clinically normal hearing were grouped into two (I and II). The group was provided with delta frequency binaural beats and II was provided with white noise stimulation (both of 20 min duration) for 30 days. Post 30 days, the re-assessment of tinnitus handicap, depression, anxiety, and quality of life parameters were performed and compared with that of pre-treatment scores.
RESULTS: A considerable reduction of tinnitus handicap scores, depression and anxiety levels were observed for both the groups, except for the quality-of-life parameters. However, few of the participants showed limited or negligible improvement post-treatment. On comparison of reduction of scores observed across the groups, there was a higher reduction of scores observed for group I when compared to group II.
CONCLUSION: The current study was an initial attempt to study the efficacy of binaural beats in treatment of individuals with tinnitus having normal hearing. Apart from a few individuals, the delta wave stimulation acted as a helpful tool in improving tinnitus borne distress symptoms in such patients with normal hearing. The results of the present study put forward the scope of adapting binaural beats stimulation for the treatment of individuals presenting with tinnitus having normal hearing sensitivity. This technique could be adopted into clinical practice after extensive research involving an extended treatment duration on a larger population.
OBJECTIVES: The aim of this study is to assess the association between atrial fibrillation (AF) and sudden sensorineural hearing loss (SSNHL).
METHODS: This study was conducted by searching the longitudinal health insurance database of the Taiwan National Health Insurance Program for relevant information from January 1, 2000, to December 31, 2011. Patients with AF were matched with non-AF controls with a 1:1 strategy according to propensity scores. Multiple logistic regression analyses were performed to determine the risk of SSNHL.
RESULTS: In total, 14 698 patients with AF were matched with the same number of non-AF patients as controls. After propensity score matching, the use of antiplatelet or anticoagulation medications and the occurrence of SSNHL were found to have a significant difference between AF and non-AF patients. The occurrence of SSNHL was found to be higher in men, those of 45 to 74 years old, and patients with hypertension in both AF and non-AF groups. Multiple logistic regression analyses revealed that male gender, age between 45 and 74 years, hyperlipidemia, and hypertension are risk factors for SSNHL. The use of aspirin was found to reduce the rate of SSNHL (odds ratio [OR]: 0.67, 95% CI: 0.49-0.94, P = .019), but AF was not found to be a risk factor for SSNHL (OR: 0.89, 95% CI: 0.64-1.23, P = .467).
CONCLUSION: The association between AF and SSNHL is not significant.
Biomathematical models of fatigue capture the physiology of sleep/wake regulation and circadian rhythmicity to predict changes in neurobehavioral functioning over time. We used a biomathematical model of fatigue linked to the adenosinergic neuromodulator/receptor system in the brain as a framework to predict sleep inertia, that is, the transient neurobehavioral impairment experienced immediately after awakening. Based on evidence of an adenosinergic basis for sleep inertia, we expanded the biomathematical model with novel differential equations to predict the propensity for sleep inertia during sleep and its manifestation after awakening. Using datasets from large laboratory studies of sleep loss and circadian misalignment, we calibrated the model by fitting just two new parameters and then validated the model's predictions against independent data. The expanded model was found to predict the magnitude and time course of sleep inertia with generally high accuracy. Analysis of the model's dynamics revealed a bifurcation in the predicted manifestation of sleep inertia in sustained sleep restriction paradigms, which reflects the observed escalation of the magnitude of sleep inertia in scenarios with sleep restriction to less than ∼ 4 h per day. Another emergent property of the model involves a rapid increase in the predicted propensity for sleep inertia in the early part of sleep followed by a gradual decline in the later part of the sleep period, which matches what would be expected based on the adenosinergic regulation of non-rapid eye movement (NREM) sleep and its known influence on sleep inertia. These dynamic behaviors provide confidence in the validity of our approach and underscore the predictive potential of the model. The expanded model provides a useful tool for predicting sleep inertia and managing impairment in 24/7 settings where people may need to perform critical tasks immediately after awakening, such as on-demand operations in safety and security, emergency response, and health care.
A self-standing container holds particles of a cosmetic composition. The container may be cup-shaped or box-shaped, for example, and made of laminated paper or polystyrene. When ready to use, the user opens the container and adds liquid or gel to mix with the dry particles to form a moist cosmetic composition, so no separate mixing container or measuring cup is necessary. The composition formed is suitable for treating a user's skin and/or hair. A fill mark on the container informs the user of a proper amount of the liquid or gel to add to the container. The particles may include both ground-up and whole particles from substances such as dried botanicals (plant ingredients) and a binding agent. A cosmetic composition includes a ready-to-mix mixture of ingredients including particles from dried herbs and/or flowers and a dried food, and an essential oil.
Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
Creating a permanent wave in hair comprises contacting the hair with a first permanent wave liq. (X) which contains an S-(2-aminoethyl)isothiuronium salt of formula NH2CH2CH2S-C(NH)NH2.nHX (I) as a reducing agent at a pH of 7.0-10.0 and then setting the wave with the aid of a second liq. (Y) contg. an oxidising agent. X = Cl or Br; and n = 1-2.  Also claimed is (a) (X); (b) (Y) contg. a taurine deriv. (II) or its salt, comprising taurine with one or more halogen atoms bonded to the nitrogen atom as an oxidising agent; and (c) method for creating a permanent wave in hair by bringing it into contact with (X) and then setting the wave with (Y) contg. (II).
FIELD: organic chemistry, medicine, neurology, pharmacy. SUBSTANCE: invention relates to novel derivatives of 8-substituted-9H-1,3-dioxol[4,5-h] [2,3] benzodiazepine of the formula (I)  , method for preparing these compounds and pharmaceutical compositions comprising these active substances. Compounds of the formula (I) inhibit AMPA/kainate receptors. In compound of the formula (I) X means carbonyl or methylene group; Y means hydrogen atom or methyl group or in common with R 3  it forms valence bond; R 1 -R 3  mean values as given in the invention claim. Invention relates also to method of treatment of patients with epilepsy or neurodegenerative diseases. Invention provides preparing novel compounds eliciting the curative effect that allows to use them in medicine. EFFECT: improved preparing method, valuable medicinal properties of compounds and composition. 13 cl, 5 tbl
The effects of tinnitus on human health are receiving increasing attention, and it is currently believed that the central compensatory response caused by peripheral hearing loss is the main pathogenesis of chronic tinnitus. Tinnitus, psychological problems and sleep disorders affect and worsen each other, and should be taken seriously in treatment strategies. Chronic tinnitus treatment strategy advocates comprehensive treatment based on sound therapy, including reducing tinnitus sound perception and improving patients' negative mood and poor sleep. Whether treating tinnitus alone or treating relevant psychological problems and sleep disorders can break the vicious circle of tinnitus, psychological problems and sleep disorders. Therefore, balancing both psychological and sleep problems, is the direction of tinnitus treatment and research. The clinical study of the treatment of tinnitus should shift from the previous single tinnitus treatment mode and a single tinnitus evaluation index to the comprehensive treatment and comprehensive evaluation indicators that balance both psychotherapy and sleep improvement.
Use the lowest dose of PROMACTA to achieve and maintain a platelet count necessary to initiate and maintain antiviral therapy with pegylated interferon and ribavirin. Dose adjustments are based upon the platelet count response. Do not use PROMACTA to normalize platelet counts [see Warnings and Precautions (5.4)]. In clinical trials, platelet counts generally began to rise within the first week of treatment with PROMACTA [see Clinical Studies (14.2)].

Initial Dose Regimen: Initiate PROMACTA at a dose of 25 mg once daily. 

Monitoring and Dose Adjustment: Adjust the dose of PROMACTA in 25-mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy. Monitor platelet counts every week prior to starting antiviral therapy.

During antiviral therapy, adjust the dose of PROMACTA to avoid dose reductions of peginterferon. Monitor CBCs with differentials, including platelet counts, weekly during antiviral therapy until a stable platelet count is achieved. Monitor platelet counts monthly thereafter. Do not exceed a dose of 100 mg daily. Monitor clinical hematology and liver tests regularly throughout therapy with PROMACTA.

For specific dosage instructions for peginterferon or ribavirin, refer to their respective prescribing information.

Discontinuation: The prescribing information for pegylated interferon and ribavirin include recommendations for antiviral treatment discontinuation for treatment futility. Refer to pegylated interferon and ribavirin prescribing information for discontinuation recommendations for antiviral treatment futility.

PROMACTA should be discontinued when antiviral therapy is discontinued. Excessive platelet count responses, as outlined in Table 2, or important liver test abnormalities also necessitate discontinuation of PROMACTA [see Warnings and Precautions (5.2)].
The present invention comprises a system, a method and a computer program product for augmenting a visualisation of reality for facial injection. Reference data from a head of a patient is obtained. The head comprises a face and anatomical structures. The reference data comprises facial data and structural data. An image of the face is recorded via a camera. A spatial map is determined based on the facial data and the image. A structural displacement is determined based on the spatial map and the structural data. The image is augmented on the basis of the structural displacement and represented via a visualisation tool. Via the determination of the structural displacement, a dynamic image can be dynamically augmented on the basis of a dynamically determined structural displacement. The anatomical structures can comprise blood vessels. The structural data can comprise blood vessel data. The structural displacement can comprise a vessel displacement.
BACKGROUND/AIMS: Inborn errors of immunity (IEI) may associate with autoimmune diseases, including autoimmune liver diseases (AILD). However, both the IEI frequency and secondary effects of immunosuppressives are unknown in patients with AILD due to the lack of data. We aimed to evaluate the ratio of IEI in AILD.
MATERIALS AND METHODS: A total of 82 patients with AILD (39 autoimmune hepatitis, 32 primary biliary cholangitis, 7 variant syndromes (VS), and 4 primary sclerosing cholangitis patients) were included in this single-center, cross-sectional, and descriptive study. The patients were evaluated and classified according to diagnostic criteria for IEI.
RESULTS: Out of 82 patients with AILD, female/male ratio was 3.6. Median age of diagnosis of AILD was 45 years. We diagnosed 15 (18%) patients with immunodeficiency (ID). Inborn errors of immunity ratio was highest in VS patient group (29%). Out of 15 patients with ID, 4 (4.8%) patients had common variable immunodeficiency, 4 (4.8%) had partial immunoglobulin A deficiency, 4 (4.8%) had selective immunoglobulin M deficiency, and 3 (3.6%) had combined immunodeficiency.
CONCLUSION: We detect ID in about one-fifth of the patients with AILD. The present study showed a significant risk of IEI that is blurred by the shadow of immune suppressive treatments. We suggest that the AILD patients with ID will benefit from the individualized and targeted therapeutic options used in IEI. Further research with larger patient groups and long-term follow-up are desperately needed to elucidate the diagnostic, therapeutic, and prognostic impacts of IEI-related individualized therapy on AILD patients.
A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
The invention discloses a traditional Chinese medicine composition for treating feed intake reduction of poultry. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-30 parts of hawthorn, 10-20 parts of smoked plum, 5-10 parts of rice sprout, 10-15 parts of malt, 20-35 parts of Medicated Leaven, 15-25 parts of bile salt and 3-5 parts of garlic. When applied to the poultry, the traditional Chinese medicine composition for treating the feed intake reduction of the poultry can take effect of regulating qi to promote appetite, removing toxin to stop dysentery and invigorating stomach to help digestion. When laying hens are suffered from diseases to cause the feed intake reduction to cause the laying rate to be obviously lowered, the efficiency is 98.8 percent, and the effective rate is 99.9 percent by adopting the traditional Chinese medicine composition. When the feed intake reduction is caused to broiler chickens because of diseases, varieties, environments and the like, the efficiency is 97.3 percent, and the effective rate is 99.5 percent by adopting the traditional Chinese medicine composition. The production process is free of toxin, harm and drug residues. As conventional equipment is adopted, the process is simple, the cost is lower, and industrialization can be easily realized.
Glutamine is a critical amino acid that serves as an energy source, building block, and signaling molecule for the heart tissue and the immune system. However, the role of glutamine metabolism in regulating cardiac remodeling following myocardial infarction (MI) is unknown. In this study, we show in adult male mice that glutamine metabolism is altered both in the remote (contractile) area and in infiltrating macrophages in the infarct area after permanent left anterior descending artery occlusion. We found that metabolites related to glutamine metabolism were differentially altered in macrophages at days 1, 3, and 7 after MI using untargeted metabolomics. Glutamine metabolism in live cells was increased after MI relative to no MI controls. Gene expression in the remote area of the heart indicated a loss of glutamine metabolism. Glutamine administration improved left ventricle (LV) function at days 1, 3, and 7 after MI, which was associated with improved contractile and metabolic gene expression. Conversely, administration of BPTES, a pharmacological inhibitor of glutaminase-1, worsened LV function after MI. Neither glutamine nor BPTES administration impacted gene expression or bioenergetics of macrophages isolated from the infarct area. Our results indicate that glutamine metabolism plays a critical role in maintaining LV contractile function following MI and that glutamine administration improves LV function. Glutamine metabolism may also play a role in regulating macrophage function, but macrophages are not responsive to exogenous pharmacological manipulation of glutamine metabolism.NEW & NOTEWORTHY Glutamine metabolism is altered in both infarct macrophages and the remote left ventricle (LV) following myocardial infarction (MI). Supplemental glutamine improves LV function following MI while inhibiting glutamine metabolism with BPTES worsens LV function. Supplemental glutamine or BPTES does not impact macrophage immunometabolic phenotypes after MI.
The invention aims to provide an antiparasitic compound with high activity and sustained effect, and a preparation method thereof. The antiparasitic compound has the molecular formula C36H50O7. The preparation method of the antiparasitic compound comprises the preparation of a culture medium, plate and slant culture, seed culture, the fermentation of a shake flask, the separation and purification of the compound and silica gel chromatography. The compound is a new compound 1 with the activity of resisting animal endoparasites, ectoparasites and ova thereof. Moxidectin at the dosage of 200 mu g/kg can suppress nematode infection in pig bodies for 35 days and suppress the appearance of the ova of nematodes for 80 days. Compared with the Moxidectin sold in the present market, under the same experimental environment and at the same dosage, the new compound prepared by the method has higher activity of resisting a plurality of parasites.
The studies on the molecular classification of endometrioid carcinoma (EC) with microcystic, elongated, and fragmented (MELF) pattern invasion are limited. In this study, 77 cases of ECs with MELF patterns in Chinese women were collected. The molecular classification of the fifth edition of the World Health Organization was used to classify the molecular subtypes using immunohistochemistry staining (mismatch repair [MMR]-immunohistochemistry: MSH2, MSH6, MLH1, and PMS2; p53) and Sanger sequencing targeted POLE . The results showed that the prevalence of the 4 molecular subtypes in EC with MELF pattern was 6.5% (5/77) for POLE mutation, 20.8% (16/77) for MMR deficient, 11.7% (9/77) for p53-mutant, and 61.0% (47/77) for no specific molecular profile. The clinicopathological characteristics of each subtype were compared. The p53-mutant and no specific molecular profile subgroups were associated with higher International Federation of Gynecology and Obstetrics stage and International Federation of Gynecology and Obstetrics grade, deeper myometrial invasion, lymphovascular space invasion, lymph node metastasis, and absence of tumor-infiltrating lymphocytes, whereas the POLE mutation and MMR deficient subgroups were associated with lower aggressive features and prominent tumor-infiltrating lymphocytes. Progression-free survival showed that the p53-mutant and no specific molecular profile subgroups had a poorer prognosis than the POLE mutation and MMR deficient subgroups. However, lymph node metastasis was an independent factor associated with a higher risk of disease recurrence in multivariate analysis. In conclusion, ECs with MELF patterns can be divided into 4 molecular subtypes with discrepancies in aggressive clinicopathological characteristics and tumor-infiltrating lymphocytes. Molecular classification has clinical significance in a morpho-molecular approach for ECs with MELF patterns.
Participant received dose of 500 mg/kg of intravenous VTS-270 administered over 2 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
The multifaceted action of new ibuprofen analogs has been investigated against inflammation, neurological and pro-inflammation factors. On the basis of ADMET (absorption, distribution, metabolism, excretion, and toxicity) analysis, molecular docking as well as molecular dynamics simulation, compound 3 was thought to have good anti-inflammatory activity. As the presence of structural interactions such as conventional hydrogen bonds and electrostatic interactions through the nitrogen atoms of the linker in compound 3 gave strong evidence of its potency. The major finding of the current work is that the presence of appropriate number of hetero atoms (NH, OH) in a compound makes it more efficient than the number of labile groups (i.e., hydroxyl groups). Additionally, the position of hetero atoms in a compound and orientation also play a vital role in its efficacy. It was also screened for in vitro anti-inflammatory activity by membrane stability method, where it has shown 90.8% protection of RBC hemolysis. Thus, compound 3 with effective structural features may have good anti-inflammatory activity.Communicated by Ramaswamy H. Sarma.
Provided herein are multispecific antibodies that bind to BCMA, GPRC5D and CD3 and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are antibodies that bind to BCMA and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided BCMA-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled BCMA-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided BCMA-specific antibodies and antigen-binding fragments are described.
Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
In obese patients, OSA prevalence is around 40% in men and 30% in women. Being overweight or obese are independent risk factors for OSA, and the prevalence increases with body mass index (BMI). Weight loss after bariatric surgery is one treatment for OSA, 75% of patients having a reduction in OSA severity or becoming non-apneic. OSA and obesity both induce type 2 diabetes, hypertension and/or nonalcoholic fatty liver disease (NAFLD). A randomized study (Chirinos et al. NEJM 2014) demonstrated a better improvement in blood pressure, triglyceride levels or insulin resistance with weight loss alone or weight loss associated with continuous positive airway pressure (CPAP) than with CPAP alone. We hypothesize a similar effect of nutritional and psychocomportemental rehabilitation on OSA. However, weight loss and blood pressure improvements could be lesser in untreated OSA patients than in treated OSA or non-OSA patients. It has been demonstrated that bariatric surgery reduces medication use such as antihypertensive or antidiabetic drugs, and thus a secondary objective is to determine whether nutritional and psychocomportemental rehabilitation similarly reduces medication use by the overweight and obese.